UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 357

Sortiert nach

Which prognostic score in MDS? Both

Leukemia, 2015-07, Vol.29 (7), p.1447-1447

Platzbecker, U

2015

Volltextzugriff (PDF)

New Agents for Anemic Patients: Modified Activin Receptors

Leukemia research, 2017-04, Vol.55, p.S3-S3

Platzbecker, U

2017

Volltextzugriff (PDF)

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2021-02, Vol.32 (2), p.142-156

2021

Volltextzugriff (PDF)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Leukemia, 2012-03, Vol.26 (3), p.381-389

2012

Volltextzugriff (PDF)

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

Leukemia, 2013-06, Vol.27 (6), p.1229-1235

2013

Volltextzugriff (PDF)

9 DO WE CURE PATIENTS WITH ALLO-HCT? HOW DO WE PREVENT RELAPSE?

Leukemia research, 2015-04, Vol.39, p.S3-S3

Platzbecker, U

2015

Volltextzugriff (PDF)

Myelodysplasia is in the niche: novel concepts and emerging therapies

Leukemia, 2015-02, Vol.29 (2), p.259-268

2015

Volltextzugriff (PDF)

Molekulare und zellbasierte Krebstherapie – Quo vadis?

Der Onkologe, 2019-09, Vol.25 (Suppl 1), p.61-67

2019

Volltextzugriff (PDF)

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Blood, 2019-03, Vol.133 (10), p.1020-1030

2019

Volltextzugriff (PDF)

Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?

Leukemia, 2013-09, Vol.27 (9), p.1813-1819

2013

Volltextzugriff (PDF)

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Leukemia, 2017-09, Vol.31 (9), p.1944-1950

2017

Volltextzugriff (PDF)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

Journal of hematology and oncology, 2016-03, Vol.9 (18), p.18-18, Article 18

2016

Volltextzugriff (PDF)

I-018 Combination treatment

Leukemia research, 2013-05, Vol.37, p.S7-S7

Platzbecker, U

2013

Volltextzugriff (PDF)

THERAPEUTIC TARGETING OF INFLAMMATION

Leukemia research, 2023-05, Vol.128, p.107083, Article 107083

Platzbecker, U.

2023

Volltextzugriff (PDF)

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis

Bone marrow transplantation (Basingstoke), 2021-09, Vol.56 (9), p.2160-2172

2021

Volltextzugriff (PDF)

WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production

Journal of bone and mineral research, 2012-03, Vol.27 (3), p.575-585

2012

Volltextzugriff (PDF)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

Leukemia, 2013-06, Vol.27 (6), p.1403-1407

2013

Volltextzugriff (PDF)

Myelodysplastic syndromes and bone loss in mice and men

Leukemia, 2017-04, Vol.31 (4), p.1003-1007

2017

Volltextzugriff (PDF)

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

Leukemia, 2013-09, Vol.27 (9), p.1910-1913

2013

Volltextzugriff (PDF)

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Haematologica (Roma), 2016-07, Vol.101 (7), p.e280

2016

Volltextzugriff (PDF)

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

Leukemia, 2023-11, Vol.37 (11), p.2309-2313

2023

Volltextzugriff (PDF)

28 Optimising pre and post transplant management

Leukemia research, 2011, Vol.35, p.S10-S10

Platzbecker, U

2011

Volltextzugriff (PDF)

Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC

Leukemia, 2021-01, Vol.35 (1), p.294-294

2021

Volltextzugriff (PDF)

1 – 25 von 357

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(328)
Mit Volltextzugriff
(325)

Publikationsform

Sprache

Englisch
(334)
Japanisch
(28)
Deutsch
(22)
Bulgarisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(152)
Life Sciences & Biomedicine
(147)
Science & Technology
(147)
Hematology
(127)
Male
(94)
Oncology
(87)
Female
(86)
Middle Aged
(78)
Adult
(73)
Hematology, Oncology And Palliative Medicine
(70)
Aged
(69)
Biological And Medical Sciences
(47)
Medical Sciences
(46)
Myelodysplastic Syndromes
(45)
Leukemia
(40)
Transplantation
(38)
Treatment Outcome
(37)
Medicin Och Hälsovetenskap
(35)
Stem Cell Transplantation
(34)
Patients
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Leukemia Research
(106)
Leukemia
(52)
Hemasphere
(28)
Haematologica
(24)
Blood
(18)
Bone Marrow Transplantation
(17)
Annals Of Hematology
(8)
Annals Of Oncology
(6)
Radiologia Diagnostica
(5)
Biology Of Blood And Marrow Transplantation
(4)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Which prognostic score in MDS? Both

New Agents for Anemic Patients: Modified Activin Receptors

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

9 DO WE CURE PATIENTS WITH ALLO-HCT? HOW DO WE PREVENT RELAPSE?

Myelodysplasia is in the niche: novel concepts and emerging therapies

Molekulare und zellbasierte Krebstherapie – Quo vadis?

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

I-018 Combination treatment

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS

THERAPEUTIC TARGETING OF INFLAMMATION

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis

WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

Myelodysplastic syndromes and bone loss in mice and men

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

28 Optimising pre and post transplant management

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)

Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC

Suchergebnisse filtern